84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004244-33-DE (EUCTR) | 21/10/2019 | 15/07/2019 | A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis | Pulmonary Sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ATYR1923 Product Code: ATYR1923 INN or Proposed INN: Not yet available Other descriptive name: iMod.Fc, H-Fcv3-N4 | aTyr Pharma, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Germany |